Zydus gets USFDA nod for drug used treat knee osteoarthritis
New Delhi: Zydus Cadila has received final approval from the US health regulator to market Diclofenac Sodium Topical Solution, used for treating signs and symptoms of osteoarthritis of the knees.
It is a non-steroidal anti-inflammatory drug, the company said in a BSE filing.
The drug will be produced at the group's topical manufacturing facility at Ahmedabad, it said.
The company has got final approval from the US Food and Drug Administration (USFDA) to market the solution, 1.5%w/w.
The Zydus group has more than 185 approvals and so far filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd